2024-12-18 17:46:05.AIbase.14.1k
AI Drug Development Company Genesis Secures Additional Investment from Nvidia to Accelerate Structure-Driven Drug Design
AI drug development company Genesis Therapeutics recently announced that it has secured additional investment from Nvidia's venture capital arm, NVentures, though the specific amount remains undisclosed. This move marks a further deepening of the collaboration between the two parties, aimed at accelerating the development of Genesis's AI platform GEMS (Genesis Exploration of Molecular Space), which focuses on utilizing physics-based AI for structure-driven drug design.
